Study of HS-10365 for RET fusion-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your tumor must test positive for a RET fusion using a central lab.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You cannot have had prior treatment with a selective RET inhibitor or multi-kinase inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SNH-118110 in patients with advanced solid tumors that have a specific genetic change (RET alteration). The drug is designed to target and slow down cancer cells with this mutation. You may qualify if your cancer has this genetic change and standard treatments haven't worked or you couldn't tolerate them.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
Hear when a new Nonsmall Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.